Phase 3 psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase 3 is a registry phase value. Large studies that compare an intervention against a control or a standard approach, often to support a regulatory decision. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 72 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 14 |
| MDMA | 7 |
| LSD | 3 |
| Ketamine | 48 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 19 | 26% |
| Not yet recruiting | 4 | 6% |
| Enrolling by invitation | 1 | 1% |
| Active, not recruiting | 10 | 14% |
| Completed | 27 | 38% |
| Suspended | 1 | 1% |
| Withdrawn | 5 | 7% |
| Status not reported | 5 | 7% |
Countries
Country is taken from the study's linked research site. 1 of 72 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 44 | 61% |
| Canada | 6 | 8% |
| France | 5 | 7% |
| Israel | 3 | 4% |
| Austria | 2 | 3% |
| Mexico | 2 | 3% |
| Argentina | 1 | 1% |
| Brazil | 1 | 1% |
| Spain | 1 | 1% |
| Ireland | 1 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 31 |
| 2020 to 2023 | 15 |
| 2015 to 2019 | 23 |
| 2010 to 2014 | 2 |
| Before 2010 | 1 |
Study design
- 72 interventional and 0 observational studies.
- Median planned or actual enrolment is 121 participants (range 16 to 1,254, across 67 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 43 |
| Suicidal thoughts | 13 |
| Trauma and PTSD | 8 |
| Pain and headache | 3 |
| Anxiety | 2 |
| Alcohol use | 2 |
| Other substance use | 2 |
| Cancer and end of life | 2 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07839338 | A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes | Not yet recruiting | Phase 3 | India | 2026-10 |
| NCT07716098 | A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | Recruiting | Phase 3 | Taiwan | 2026-08 |
| NCT07226232 | Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | Recruiting | Phase 3 | United States | 2026-06 |
| NCT07638553 | Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | Recruiting | Phase 3 | France | 2026-06 |
| NCT06781697 | InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | Recruiting | Phase 3 | Canada | 2026-05 |
| NCT06835504 | Morphine or Ketamine for Analgesia | Not yet recruiting | Phase 3 | United States | 2026-05 |
| NCT07703722 | Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | Recruiting | Phase 3 | Pakistan | 2026-04 |
| NCT07227454 | A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | Recruiting | Phase 3 | United States | 2026-01 |
| NCT07063862 | Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) | Recruiting | Phase 3 | Canada | 2026-01 |
| NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Recruiting | Phase 3 | United States | 2025-12 |
| NCT06943573 | Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder | Recruiting | Phase 3 | Canada | 2025-10 |
| NCT07153406 | Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients | Not yet recruiting | Phase 3 | Spain | 2025-09 |
| NCT06605105 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Enrolling by invitation | Phase 3 | United States | 2025-07 |
| NCT07088380 | Ketamine Augmentation of ECT in Treatment-Resistant Depression | Recruiting | Phase 3 | Italy | 2025-07 |
| NCT06957704 | Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents | Not yet recruiting | Phase 3 | Brazil | 2025-05 |
| NCT05603104 | Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | Recruiting | Phase 3 | Israel | 2025-04 |
| NCT06941844 | A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Active, not recruiting | Phase 3 | United States | 2025-04 |
| NCT06809595 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Active, not recruiting | Phase 3 | United States | 2025-01 |
| NCT06713616 | PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | Recruiting | Phase 3 | United States | 2025-01 |
| NCT06564818 | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Active, not recruiting | Phase 3 | United States | 2024-12 |
| NCT06741228 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Active, not recruiting | Phase 3 | United States | 2024-12 |
| NCT06117306 | MDMA-assisted Massed Prolonged Exposure for PTSD | Active, not recruiting | Phase 3 | United States | 2024-10 |
| NCT06508710 | Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients | Recruiting | Phase 3 | France | 2024-10 |
| NCT06752759 | Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting | Recruiting | Phase 3 | United States | 2024-10 |
| NCT06247839 | The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | Recruiting | Phase 3 | United States | 2024-09 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 4 | Phase not applicable